Oncology

Latest News

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Dordaviprone (Modeyso) is now approved to treat recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children.

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com

Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

By AJMC Contributor

July 29th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

August 13th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 13th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

January 16th 2015

Study Indicates Improved Survival in CRC Despite Lower Surgery Rates

The research, published in JAMA Surgery, analyzed data collected from NCI's SEER database, between 1988 till 2010, on stage 4 CRC patients who had surgery or not for primary tumor resection. Survival data on these patients was then analyzed and associated with their surgical status.

Predictive Value of Diagnostic Tests

January 16th 2015

Predictive Value of Diagnostic Tests

Development and Use of Diagnostic Testing

January 16th 2015

Development and Use of Diagnostic Testing

Predictive Value of Diagnostic Testing

January 16th 2015

Predictive Value of Diagnostic Testing

Clinical Utility of Genomic Testing

January 16th 2015

Clinical Utility of Genomic Testing

Use of Molecular Tests That Assess Risk of Recurrence

January 16th 2015

Use of Molecular Tests That Assess Risk of Recurrence

January 15th 2015

Spanish Team Identifies Gene Variant Responsible for Susceptibility to Peripheral Neuropathy

The authors of the research say that this information could be especially valuable for the Spanish population: "Even though these variants are rare or not frequent in the population, their frequency is greater in Spain than in other countries."

January 15th 2015

Metabolic Syndrome A Significant Risk Factor in Endometrial Cancer, Study Finds

Overall, metabolic syndrome was associated with a 39 percent to 103 percent increased risk of endometrial cancer in women 65 and older, according to the study.

January 15th 2015

Patients With Metastatic Colorectal Cancer Having Less Surgery, Yet Survival Rates Improving

With the dawn of the modern era of new chemotherapeutic and biologic agents available for managing their disease, patients with metastatic colorectal cancer are undergoing less surgery for the removal of their primary tumors.

January 15th 2015

Can We Follow the European Model to Curb Drug Costs, Asks Dr Peter Bach

In an Ope-Ed in The New York Times , Peter Bach, MD, from the Memorial Sloan Kettering Cancer Center, questions the rising drug prices and contemplates solutions.

January 14th 2015

ASCO Staff Raising Healthcare Issues with Federal and State Legislators

Members of the ASCO Government Relations Committee are busy meeting Members of Congress as well as State Affiliates to address a number of healthcare issue early in the year.

January 14th 2015

Cancer Treatments the Next Big Area for Cost Saving Opportunities

Laura Joszt, MA

Involving the pharmacy benefits manager earlier in the decision-making process could lead to cost savings on cancer treatments, Express Scripts Chief Executive Officer George Paz said at the J.P. Morgan Healthcare Conference in San Francisco, California.

January 14th 2015

Diagnostic Testing Guidelines for Lung Cancer to Be Revised

In addition to recommendations on alternate techniques, the revised guideline, being jointly developed by CAP, IASLC, and AMP, will also include testing for emerging biomarkers in lung cancer.

January 14th 2015

Express Scripts Wants Early Discussions to Help Lower Treatment Costs

After their decision to include Abbvie's triple combination for hepatitis C on their formulary, over Gilead's more expensive regimens, Express Scripts indicated at the J. P. Morgan Healthcare Conference that they'll continue the stance of choosing treatments that are equally effective but save costs, especially in cancer.

January 13th 2015

"Choose Wisely" in Rectal Cancer a Retrospective Study Indicates

The retrospective analysis of 145 patients with stage 2-3 rectal cancer found that the "wait and watch" approach, instead of surgery, in patients treated with chemotherapy might work just as well when measuring survival as an outcome.

January 13th 2015

Pharma Giants to Collaborate on Immuno-oncology Regimens

Merck and Eli Lilly have entered an agreement to collaborate on clinical trials to evaluate the former's recently approved PD-1 inhibitor, Keytruda (pembrolizumab) in combination with Lilly's oncology agents in several clinical trials targeting multiple tumor types.

January 13th 2015

Study Highlights Need to Reduce Global Teen Exposure to Second-hand Smoke

The study evaluated data collected through a global collaboration between research institutes in the United States, India, and Africa. Study results pointed to a high rate of exposure of non-smoking teenagers to second-hand smoke, both at home and outside.

January 12th 2015

Cancer Survivors Identify Lingering Medical, Financial Troubles

Laura Joszt, MA

The number of cancer survivors may be on the rise, but they experience continuing issues that can impair their quality of life beyond 5 years of survival, according to a new study published in Cancer.

January 12th 2015

Pfizer Gains Access to 23andMe's Genetic Mine

23andMe is betting its growing troves of genetic data will prove essential to drug companies, medical researchers, and even health and wellness companies.

January 12th 2015

A New Target in Difficult-to-Treat Breast Cancer?

The pre-clinical study by researchers at the Wellcome Trust Sanger Institute in UK point to the gene BCL11A as a possible driver of this aggressive form of breast cancer.

January 12th 2015

Nivolumab Phase 3 Trial in NSCLC Stopped Early; Superior OS

Mid-trial evaluation by an independent Data Monitoring Committee found overall survival with Opdivo (nivolumab) in the Checkmate-017 trial was significantly better than the control arm. BMS now plans to submit results to the FDA for approval of the PD-1 inhibitor in lung cancer.

January 9th 2015

ASCO Backs the FDA on Regulating Lab-Based Diagnostics

In comments to the House Committee on Energy and Commerce, Health Subcommittee, ASCO strongly supported the FDA's resolution to rigorously regulate laboratory-developed tests.

January 9th 2015

Age Determines HPV Persistence in Men

The study, published in the journal Cancer Prevention Research found that HPV persisted for 12 months or more in men older than 45 years of age, which could increase their susceptibility to developing head and neck cancer.

January 9th 2015

Nanotechnology, Hailed in Biomedicine, Could Have Cardiac Effects, Study Finds

While nanotechnology has led to countless advancements, a group of Israeli researchers are now raising a flag of caution about its effects on our health. They say exposure to tiny silica-based particles can play a big role in increasing heart attack and stroke risks.

January 9th 2015

Controlling Cancer Metastases To Prevent Disease Progression

Research at Heildelberg University is targeting the production of tumor-promoting growth factors in endothelial cells to prevent metastasis. Pre-clinical results using this strategy in a mouse model reduced lung and bone metastases in treated mice and also improved survival over the control chemotherapy-treated animals.

January 8th 2015

NCCN and Flatiron to Collaborate for Improved Patient-Centered Care

A new collaboration between NCCN and Flatiron Health will provide the opportunity to analyze key quality and outcomes metrics and identify trends and patterns in the care of patients with cancer.

January 8th 2015

The Debate on HPV Screening in Cervical Cancer

Following FDA approval of a DNA test to detect the HPV virus last year, the medical community is split over which test is more appropriate as a primary screen for cervical cancer in women.

January 8th 2015

Leading Cancer Research Groups Call for US Regulation of E-Cigarettes

Mary K. Caffrey

ASCO and AACR called on the FDA to regulate e-cigarettes and other electronic nicotine delivery systems and for more research to occur to find out how long-term use affects health. Leaders of these groups said that e-cigarettes could cause nicotine addiction among teens, and CDC data show rising use of the products among middle- and high-schoolers.

January 8th 2015

A Relatively Safe Breast Cancer Combination Therapy Proves Effective

The study published in the New England Journal of Medicine found nearly 100% survival with adjuvant paclitaxel and trastuzumab.

January 7th 2015

ODAC Recommends First Biosimliar for Approval to the FDA

The investigational drug by Sandoz, filgrastim, a biological similar to Amgen's Neupogen, is already approved for use in more than 40 countries worldwide.

...

144 145 146 147 148 149 150 151 152

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions